Peregrine Pharmaceuticals reported $31.51M in Sales Revenues for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Agenus AGEN:US $ 25.94M 5.68M
Amgen AMGN:US $ 6238M 608M
AstraZeneca AZN:LN 11390M 621M
Biocryst Pharmaceuticals BCRX:US $ 49.92M 2.76M
Bristol Myers Squibb BMY:US $ 11648M 337M
Celldex Therapeutics CLDX:US $ 0.17M 0.16M
Chemocentryx CCXI:US $ 5.46M 3.14M
Eli Lilly And LLY:US $ 7810M 189.9M
GlaxoSmithKline GSK:LN 9780M 253M
Immunogen IMGN:US $ 38.08M 10.09M
Intrexon XON:US $ 32.02M 7.8M
Karyopharm Therapeutics KPTI:US $ 47.67M 78.6M
Macrogenics MGNX:US $ 11.1M 3.05M
Mannkind MNKD:US $ 11.99M 0.52M
Merk MRK:US $ 15901M 2380M
Newlink Genetics NLNK:US $ 0.11M 0.11M
Novartis NOVN:VX SF 12814M 708M
Novavax NVAX:US $ 703.97M 481.77M
Peregrine Pharmaceuticals PPHM:US $ 31.51M 5.4M
Repligen RGEN:US $ 206.4M 19.88M
Roche Holding ROG:VX 16.44B 474M
Xencor XNCR:US $ 85.5M 68.52M